Table II.
Univariate and multivariate Cox regression analyses of DFS and OS in patients with breast cancer.
| Univariate analysis | Multivariate analysis | |||
|---|---|---|---|---|
| Covariates | HR (95% CI) | P-value | HR (95% CI) | P-value |
| A, DFS | ||||
| Age | ||||
| 41–65 vs. ≤40 years old | 0.434 (0.257–0.734) | 0.002 | 0.518 (0.299–0.895) | 0.018 |
| >65 vs. ≤40 years old | 0.625 (0.339–1.151) | 0.131 | 0.717 (0.377–1.366) | 0.312 |
| Menopause status (post vs. pre) | 1.002 (0.635–1.582) | 0.992 | ||
| Histology | ||||
| ILC vs. IDC | 1.297 (0.8–2.105) | 0.292 | ||
| Others vs. IDC | 1.667 (0.83–3.349) | 0.151 | ||
| pT stage | ||||
| T2 vs. T1 | 1.794 (1.041–3.093) | 0.035 | 1.678 (0.957–2.942) | 0.071 |
| T3 vs. T1 | 2.579 (1.338–4.97) | 0.005 | 2.408 (1.194–4.855) | 0.014 |
| T4 vs. T1 | 7.541 (3.068–18.531) | 0.000 | 3.784 (1.447–9.899) | 0.007 |
| pN stage (positive vs. negative) | 1.969 (1.295–2.993) | 0.002 | 1.808 (1.159–2.822) | 0.009 |
| ER (positive vs. negative) | 0.535 (0.351–0.815) | 0.004 | 0.782 (0.418–1.464) | 0.443 |
| PR (positive vs. negative) | 0.514 (0.342–0.771) | 0.001 | 0.574 (0.316–1.041) | 0.068 |
| HER2 (positive vs. negative) | 0.781 (0.412–1.484) | 0.451 | ||
| CD4 expression level (high vs. low) | 0.794 (0.525–1.202) | 0.276 | ||
| CD8A expression level (high vs. low) | 0.608 (0.403–0.918) | 0.018 | 0.575 (0.371–0.891) | 0.013 |
| FOXP3 expression level (high vs. low) | 0.634 (0.406–0.988) | 0.044 | 0.595 (0.374–0.947) | 0.028 |
| B, OS | ||||
| Univariate analysis | Multivariate analysis | |||
| Covariates | HR (95% CI) | P-value | HR (95% CI) | P-value |
| Age | ||||
| 41–65 vs. ≤40 years old | 0.58 (0.331–1.016) | 0.057 | 0.553 (0.284–1.076) | 0.081 |
| >65 vs. ≤40 years old | 1.785 (1.021–3.123) | 0.042 | 1.73 (0.806–3.71) | 0.159 |
| Menopause status (post versus pre) | 2.135 (1.246–3.661) | 0.006 | 1.638 (0.831–3.23) | 0.154 |
| Histology | ||||
| ILC vs. IDC | 1.082 (0.688–1.699) | 0.734 | ||
| Others vs. IDC | 1.521 (0.812–2.849) | 0.191 | ||
| pT stage | ||||
| T2 vs. T1 | 1.361 (0.875–2.116) | 0.172 | 1.35 (0.851–2.141) | 0.203 |
| T3 vs. T1 | 1.559 (0.884–2.749) | 0.125 | 1.347 (0.736–2.467) | 0.334 |
| T4 vs. T1 | 3.277 (1.524–7.046) | 0.002 | 1.945 (0.861–4.39) | 0.109 |
| pN stage (positive vs. negative) | 1.884 (1.301–2.727) | 0.001 | 1.852 (1.244–2.757) | 0.002 |
| ER (positive vs. negative) | 0.631 (0.427–0.933) | 0.021 | 0.574 (0.381–0.865) | 0.008 |
| PR (positive vs. negative) | 0.733 (0.506–1.062) | 0.101 | ||
| HER2 (positive vs. negative) | 1.391 (0.852–2.271) | 0.187 | ||
| CD4 expression level (high vs. low) | 0.649 (0.440–0.957) | 0.029 | 0.781 (0.522–1.169) | 0.229 |
| CD8A expression level (high vs. low) | 0.562 (0.385–0.82) | 0.003 | 0.637 (0.426–0.953) | 0.028 |
| FOXP3 expression level (high vs. low) | 0.967 (0.668–1.398) | 0.857 | ||
CI, confidence interval; HR, hazard ratio; DFS, disease-free survival; OS, overall survival; BC, breast cancer; ILC, invasive lobular carcinoma; IDC, invasive ductal carcinoma; pT stage, pathological stage according to the tumor size; T1, tumor size ≤2 cm; T2, tumor size 2–5 cm; T3, tumor size >5 cm; T4, tumor invades the chest wall or skin; pN stage, pathological stage according to the lymph node metastasis; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor-2; FOXP3, forkhead box P3; CD, cluster of differentiation.